269 related articles for article (PubMed ID: 24312298)
21. Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model.
Gombash SE; Lipton JW; Collier TJ; Madhavan L; Steece-Collier K; Cole-Strauss A; Terpstra BT; Spieles-Engemann AL; Daley BF; Wohlgenant SL; Thompson VB; Manfredsson FP; Mandel RJ; Sortwell CE
Mol Ther; 2012 Mar; 20(3):544-54. PubMed ID: 22008908
[TBL] [Abstract][Full Text] [Related]
22. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease.
Gorbatyuk OS; Li S; Sullivan LF; Chen W; Kondrikova G; Manfredsson FP; Mandel RJ; Muzyczka N
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):763-8. PubMed ID: 18178617
[TBL] [Abstract][Full Text] [Related]
23. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease.
Dusonchet J; Bensadoun JC; Schneider BL; Aebischer P
Neurobiol Dis; 2009 Jul; 35(1):32-41. PubMed ID: 19348945
[TBL] [Abstract][Full Text] [Related]
24. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
Eslamboli A; Romero-Ramos M; Burger C; Bjorklund T; Muzyczka N; Mandel RJ; Baker H; Ridley RM; Kirik D
Brain; 2007 Mar; 130(Pt 3):799-815. PubMed ID: 17303591
[TBL] [Abstract][Full Text] [Related]
25. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
[TBL] [Abstract][Full Text] [Related]
26. Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration.
Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Luk KC; Tansey MG; Paumier KL; Kanaan NM; Fischer DL; Polinski NK; Barth OL; Howe JW; Vaikath NN; Majbour NK; El-Agnaf OMA; Sortwell CE
J Neuroinflammation; 2018 May; 15(1):129. PubMed ID: 29716614
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
Van der Perren A; Toelen J; Casteels C; Macchi F; Van Rompuy AS; Sarre S; Casadei N; Nuber S; Himmelreich U; Osorio Garcia MI; Michotte Y; D'Hooge R; Bormans G; Van Laere K; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
Neurobiol Aging; 2015 Mar; 36(3):1543-58. PubMed ID: 25599874
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Decressac M; Mattsson B; Björklund A
Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
[TBL] [Abstract][Full Text] [Related]
29. In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration.
Gorbatyuk OS; Li S; Nash K; Gorbatyuk M; Lewin AS; Sullivan LF; Mandel RJ; Chen W; Meyers C; Manfredsson FP; Muzyczka N
Mol Ther; 2010 Aug; 18(8):1450-7. PubMed ID: 20551914
[TBL] [Abstract][Full Text] [Related]
30. In vivo quantification of glial activation in minipigs overexpressing human α-synuclein.
Lillethorup TP; Glud AN; Landeck N; Alstrup AKO; Jakobsen S; Vang K; Doudet DJ; Brooks DJ; Kirik D; Hinz R; Sørensen JC; Landau AM
Synapse; 2018 Dec; 72(12):e22060. PubMed ID: 30009467
[TBL] [Abstract][Full Text] [Related]
31. Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration.
Jimenez-Ferrer I; Jewett M; Tontanahal A; Romero-Ramos M; Swanberg M
Neurobiol Dis; 2017 Oct; 106():279-290. PubMed ID: 28736195
[TBL] [Abstract][Full Text] [Related]
32. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease.
Kirik D; Annett LE; Burger C; Muzyczka N; Mandel RJ; Björklund A
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2884-9. PubMed ID: 12601150
[TBL] [Abstract][Full Text] [Related]
33. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease.
Koprich JB; Johnston TH; Reyes MG; Sun X; Brotchie JM
Mol Neurodegener; 2010 Oct; 5():43. PubMed ID: 21029459
[TBL] [Abstract][Full Text] [Related]
34. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.
Naughton C; O'Toole D; Kirik D; Dowd E
Behav Brain Res; 2017 Jan; 316():160-168. PubMed ID: 27585560
[TBL] [Abstract][Full Text] [Related]
35. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
[TBL] [Abstract][Full Text] [Related]
36. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.
Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW
Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147
[TBL] [Abstract][Full Text] [Related]
37. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
38. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A
Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897
[TBL] [Abstract][Full Text] [Related]
39. Viral mimetic priming enhances α-synuclein-induced degeneration: Implications for Parkinson's disease.
Olsen LK; Cairns AG; Ådén J; Moriarty N; Cabre S; Alamilla VR; Almqvist F; Dowd E; McKernan DP
Brain Behav Immun; 2019 Aug; 80():525-535. PubMed ID: 31029796
[TBL] [Abstract][Full Text] [Related]
40. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]